Candriam S.C.A. Sells 91,955 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Candriam S.C.A. decreased its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 35.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 169,550 shares of the biopharmaceutical company’s stock after selling 91,955 shares during the period. Candriam S.C.A.’s holdings in Agios Pharmaceuticals were worth $5,571,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp grew its holdings in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after acquiring an additional 216,484 shares during the period. Vestal Point Capital LP purchased a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth approximately $33,767,000. BNP Paribas Financial Markets grew its holdings in shares of Agios Pharmaceuticals by 15.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 1,570 shares during the period. FMR LLC grew its stake in shares of Agios Pharmaceuticals by 283.2% in the 3rd quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company’s stock worth $2,017,000 after buying an additional 33,546 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $892,000.

Insider Buying and Selling

In related news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Scotiabank upped their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Royal Bank of Canada increased their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Finally, HC Wainwright initiated coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 target price on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $32.38 on Friday. The business’s fifty day moving average price is $33.80 and its 200-day moving average price is $42.31. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of 2.86 and a beta of 0.90. Agios Pharmaceuticals, Inc. has a 1-year low of $27.14 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.